Effective NAION neuroregenerative treatment using TXA127

Bernstein, Steven L.; Woo, Kwang Min; Guo, Yan, M.D.; Mehrabyan, Zara

The UMB Digital Archive is getting an upgrade! The upgrade requires a content freeze starting 1/27/25 and is expected to last two weeks. Any new user accounts or submissions made to the Archive during this time will not be transferred to the upgraded site. Contact ArchiveHelp@hshsl.umaryland.edu for questions.

Show simple item record

dc.contributor.author	Bernstein, Steven L.
dc.contributor.author	Woo, Kwang Min
dc.contributor.author	Guo, Yan, M.D.
dc.contributor.author	Mehrabyan, Zara
dc.date.accessioned	2024-05-23T15:59:30Z
dc.date.available	2024-05-23T15:59:30Z
dc.date.issued	2024-05-04
dc.identifier.uri	http://hdl.handle.net/10713/22435
dc.description	Association for Vision and Ophthalmology (ARVO) convention. May 4, 2024.	en_US
dc.description.abstract	Current approaches to treatment of nonarteritic anterior ischemic optic neuropathy (NAION) rely on early retinal ganglion cell (RGC) neuroprotection. However, current neuroprotective approaches have been ineffective when administered late (>1d) after induction in rodent and primate NAION models. This is particularly problematic clinically, since nearly all patients are diagnosed at least a day post-symptom onset. We report on the success of a new neuroregenerative approach using TXA127, a pharmaceutical formulation of angiotensin (1-7) currently in Phase II for ischemic stroke.	en_US
dc.language.iso	en_US	en_US
dc.rights	Attribution-NonCommercial-NoDerivatives 4.0 International	*
dc.rights.uri	http://creativecommons.org/licenses/by-nc-nd/4.0/	*
dc.subject.mesh	Optic Nerve	en_US
dc.subject.mesh	Optic Neuropathy, Ischemic	en_US
dc.subject.mesh	Neuroprotection	en_US
dc.title	Effective NAION neuroregenerative treatment using TXA127	en_US
dc.type	Poster/Presentation	en_US
refterms.dateFOA	2024-05-23T15:59:31Z